U.S. Markets closed

Opiant Pharmaceuticals, Inc. (OPNT)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
40.58+3.61 (+9.76%)
At close: 4:00PM EDT
People also watch
Full screen
Previous Close36.97
Bid37.77 x 100
Ask51.00 x 100
Day's Range37.15 - 41.94
52 Week Range5.00 - 51.90
Avg. Volume70,642
Market Cap82.24M
PE Ratio (TTM)15.26
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Forbes4 days ago

    Opiant Up Nearly 30% On Favorable Zacks Report

    Opiant Pharmaceuticals jumped nearly 30% yesterday on a favorable report from Zacks, making it the forth largest position in Todd Hagopian's Biotech Fund. Here's what Todd thinks of the news.

  • Zacks Small Cap Research5 days ago

    OPNT: Estimating When Royalties to NARCAN® Nasal Spray Revert Back to Opiant

    On December 15, 2016, Opiant Pharmaceuticals, Inc. (OPNT) announced an agreement with SWK Holdings Corporation whereby SWK acquired the rights to certain royalty and milestone payments related to the sale of NARCAN® Nasal Spray for an initial payment of $13.7 million and the potential for an additional $3.75 million if certain future net sales milestones are met. On August 10, 2017, Opiant announced an additional $3.75 million payment from SWK related to the royalty monetization agreement related to the sale of NARCAN® Nasal Spray signed between Opiant and SWK in December 2016. According to the agreement, the $3.75 million payment was due to Opiant upon Adapt Pharma recording $25 million in cumulative net sales of NARCAN® Nasal Spray for any two consecutive quarters from Oct. 1, 2016 to Sep. 30, 2017.

  • Zacks Small Cap Research26 days ago

    OPNT: Uplists to NASDAQ

    By David Bautz, PhD NASDAQ:OPNT Opiant Uplists to the Nasdaq Stock Exchange On August 28, 2017, Opiant Pharmaceuticals Inc. (NASDAQ:OPNT) announced its shares of common stock were approved for listing ...